Northwest Biotherapeutics, Inc. (NWBO)
USD 0.21
(-1.87%)
USD 0.21
(-1.87%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -25.79 Million USD | 47.41% |
| 2022 | 135 Thousand USD | 100.7% |
| 2021 | -19.3 Million USD | 40.32% |
| 2020 | -32.34 Million USD | -176.56% |
| 2019 | -11.69 Million USD | 34.08% |
| 2018 | -17.74 Million USD | 46.53% |
| 2017 | -33.17 Million USD | 44.2% |
| 2016 | -59.45 Million USD | 41.35% |
| 2015 | -101.38 Million USD | -20.43% |
| 2014 | -84.18 Million USD | -95.33% |
| 2013 | -43.09 Million USD | -53.17% |
| 2012 | -28.13 Million USD | -281460.0% |
| 2011 | 10 Thousand USD | 0.0% |
| 2010 | 10 Thousand USD | 0.0% |
| 2009 | 10 Thousand USD | 0.0% |
| 2008 | 10 Thousand USD | 600.0% |
| 2007 | -2000.00 USD | -100.25% |
| 2006 | 790 Thousand USD | 605.36% |
| 2005 | 112 Thousand USD | -68.0% |
| 2004 | 350 Thousand USD | -22.22% |
| 2003 | 450 Thousand USD | 22400.0% |
| 2002 | 2000.00 USD | -96.8% |
| 2001 | 62.5 Thousand USD | -40.54% |
| 2000 | 105.11 Thousand USD | -34.3% |
| 1999 | 160 Thousand USD | -48.39% |
| 1998 | 310 Thousand USD | -35.42% |
| 1997 | 480 Thousand USD | 108.7% |
| 1996 | 230 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -221 Thousand USD | -1020.83% |
| 2024 Q2 | -6000.00 USD | 97.29% |
| 2023 Q2 | -220 Thousand USD | -146.03% |
| 2023 FY | 199 Thousand USD | 47.41% |
| 2023 Q1 | 478 Thousand USD | 186.23% |
| 2023 Q4 | 24 Thousand USD | 128.92% |
| 2023 Q3 | -83 Thousand USD | 62.27% |
| 2022 Q4 | 167 Thousand USD | 200.0% |
| 2022 Q1 | 243 Thousand USD | 121.22% |
| 2022 FY | 135 Thousand USD | 100.7% |
| 2022 Q3 | -167 Thousand USD | 98.73% |
| 2022 Q2 | -13.16 Million USD | -5518.93% |
| 2021 Q3 | -3.39 Million USD | 32.51% |
| 2021 Q4 | -1.14 Million USD | 66.3% |
| 2021 Q1 | -6.68 Million USD | 20.4% |
| 2021 Q2 | -5.03 Million USD | 24.67% |
| 2021 FY | -19.3 Million USD | 40.32% |
| 2020 FY | -32.34 Million USD | -176.56% |
| 2020 Q3 | -17.44 Million USD | -442.08% |
| 2020 Q2 | -3.21 Million USD | 2.1% |
| 2020 Q1 | -3.28 Million USD | -5.45% |
| 2020 Q4 | -8.39 Million USD | 51.86% |
| 2019 Q2 | -2.71 Million USD | -1.69% |
| 2019 FY | -11.69 Million USD | 34.08% |
| 2019 Q4 | -3.11 Million USD | -5.84% |
| 2019 Q3 | -2.94 Million USD | -8.67% |
| 2019 Q1 | -2.66 Million USD | 37.94% |
| 2018 FY | -17.74 Million USD | 46.53% |
| 2018 Q1 | -4.6 Million USD | 65.3% |
| 2018 Q2 | -5 Million USD | -8.76% |
| 2018 Q3 | -3.84 Million USD | 23.2% |
| 2018 Q4 | -4.29 Million USD | -11.74% |
| 2017 Q3 | -9.57 Million USD | -78.0% |
| 2017 FY | -33.17 Million USD | 44.2% |
| 2017 Q4 | -13.26 Million USD | -38.53% |
| 2017 Q2 | -5.37 Million USD | -8.27% |
| 2017 Q1 | -4.96 Million USD | 70.37% |
| 2016 Q3 | -20.93 Million USD | -144.68% |
| 2016 Q1 | -13.2 Million USD | 71.1% |
| 2016 Q4 | -16.76 Million USD | 19.93% |
| 2016 Q2 | -8.55 Million USD | 35.2% |
| 2016 FY | -59.45 Million USD | 41.35% |
| 2015 Q1 | -19.43 Million USD | 5.32% |
| 2015 FY | -101.38 Million USD | -20.43% |
| 2015 Q3 | -8.84 Million USD | 67.72% |
| 2015 Q4 | -45.69 Million USD | -416.5% |
| 2015 Q2 | -27.4 Million USD | -41.05% |
| 2014 Q2 | -21.54 Million USD | -7.82% |
| 2014 Q3 | -22.12 Million USD | -2.67% |
| 2014 Q4 | -20.52 Million USD | 7.24% |
| 2014 Q1 | -19.98 Million USD | -79.71% |
| 2014 FY | -84.18 Million USD | -95.33% |
| 2013 Q3 | -12.39 Million USD | -52.8% |
| 2013 Q1 | -11.47 Million USD | -42.44% |
| 2013 FY | -43.09 Million USD | -53.17% |
| 2013 Q4 | -11.12 Million USD | 10.27% |
| 2013 Q2 | -8.11 Million USD | 29.29% |
| 2012 Q3 | -9.82 Million USD | -3076.97% |
| 2012 Q1 | - USD | 0.0% |
| 2012 FY | -28.13 Million USD | -281460.0% |
| 2012 Q4 | -8.05 Million USD | 18.03% |
| 2012 Q2 | 330 Thousand USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | 10 Thousand USD | 0.0% |
| 2011 Q4 | - USD | -100.0% |
| 2011 Q3 | 10 Thousand USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | 10 Thousand USD | 0.0% |
| 2010 FY | 10 Thousand USD | 0.0% |
| 2010 Q4 | - USD | -100.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | 10 Thousand USD | 0.0% |
| 2009 Q4 | - USD | -100.0% |
| 2009 FY | 10 Thousand USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q3 | 10 Thousand USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q4 | - USD | -100.0% |
| 2008 FY | 10 Thousand USD | 600.0% |
| 2007 Q1 | - USD | -100.0% |
| 2007 Q3 | 10 Thousand USD | 0.0% |
| 2007 FY | -2000.00 USD | -100.25% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q4 | - USD | -100.0% |
| 2006 Q4 | 710 Thousand USD | 787.5% |
| 2006 Q1 | - USD | -100.0% |
| 2006 Q3 | 80 Thousand USD | 0.0% |
| 2006 FY | 790 Thousand USD | 605.36% |
| 2006 Q2 | - USD | 0.0% |
| 2005 FY | 112 Thousand USD | -68.0% |
| 2005 Q4 | 10 Thousand USD | -16.67% |
| 2005 Q3 | 12 Thousand USD | 71.43% |
| 2005 Q2 | 7000.00 USD | -91.76% |
| 2005 Q1 | 85 Thousand USD | 57.41% |
| 2004 FY | 350 Thousand USD | -22.22% |
| 2004 Q4 | 54 Thousand USD | -34.94% |
| 2004 Q3 | 83 Thousand USD | -24.55% |
| 2004 Q2 | 110 Thousand USD | 7.84% |
| 2004 Q1 | 102 Thousand USD | -8.11% |
| 2003 Q1 | 69 Thousand USD | 3550.0% |
| 2003 FY | 450 Thousand USD | 22400.0% |
| 2003 Q4 | 111 Thousand USD | -9.76% |
| 2003 Q3 | 123 Thousand USD | -16.33% |
| 2003 Q2 | 147 Thousand USD | 113.04% |
| 2002 Q3 | 234.00 USD | -83.01% |
| 2002 Q1 | 389.00 USD | -99.2% |
| 2002 FY | 2000.00 USD | -96.8% |
| 2002 Q4 | -2000.00 USD | -954.7% |
| 2002 Q2 | 1377.00 USD | 253.98% |
| 2001 Q4 | 48.44 Thousand USD | 96.37% |
| 2001 FY | 62.5 Thousand USD | -40.54% |
| 2001 Q3 | 24.67 Thousand USD | 0.0% |
| 2001 Q1 | 24.67 Thousand USD | 23.36% |
| 2001 Q2 | 24.67 Thousand USD | 0.0% |
| 2000 Q4 | 20 Thousand USD | 0.0% |
| 2000 FY | 105.11 Thousand USD | -34.3% |
| 2000 Q3 | 20 Thousand USD | 0.0% |
| 1999 FY | 160 Thousand USD | -48.39% |
| 1998 FY | 310 Thousand USD | -35.42% |
| 1997 FY | 480 Thousand USD | 108.7% |
| 1996 FY | 230 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -1057628.577% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 320.383% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -7974.314% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 121.659% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -53357.386% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -20662.811% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 271.998% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 831756.995% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 363.406% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 39349.635% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -75443.192% |
| Mesoblast Limited | -35.16 Million USD | 26.644% |
| Marizyme, Inc. | 457.7 Thousand USD | 5736.418% |
| Genus plc | 178.7 Million USD | 114.436% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 111.721% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 41558.554% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 6389.664% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -234427.273% |
| ContraFect Corporation | -154 Thousand USD | -16651.948% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -51496.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 33708.213% |
| IMV Inc. | -962.29 Thousand USD | -2580.874% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -6557.531% |
| MultiCell Technologies, Inc. | 49.32 USD | 52307480.373% |
| ONE Bio Corp. | 20.12 Million USD | 228.186% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 164.071% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 52856.646% |
| Q BioMed Inc. | -8988.00 USD | -286927.147% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 191.304% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -167158.817% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 158.159% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | -2159.866% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 36954.286% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -520861.228% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 18461.566% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -26355.417% |
| GB Sciences, Inc. | -624.00 USD | -4134194.872% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -29887.911% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.341% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -12402784.615% |
| Enzolytics Inc. | 30.7 Thousand USD | 84110.681% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 5447.478% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 102.327% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -4914.091% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 4278.599% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 106.299% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -291205.33% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -30667.212% |
| Kadimastem Ltd | -630.13 Thousand USD | -3994.024% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 2711.184% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 368.422% |
| BioStem Technologies, Inc. | 15.42 Million USD | 267.25% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -217880.566% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 14711.464% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 14711.464% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 2000.905% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -88858.621% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 5832.341% |
| SYBLEU INC | 11.69 Thousand USD | 220671.135% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 659.852% |
| Bioxytran, Inc. | -8285.00 USD | -311282.016% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -6816.354% |
| Neutra Corp. | 14.33 Thousand USD | 180065.12% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -31360.976% |
| PureTech Health plc | -1.6 Million USD | -1509.357% |
| Coeptis Therapeutics, Inc. | -1 Million USD | -2476.615% |
| IXICO plc | 3.27 Million USD | 888.93% |
| IntelGenx Technologies Corp. | -694 Thousand USD | -3617.291% |
| Gelesis Holdings, Inc. | -1.79 Million USD | -1340.424% |
| CSL Limited | 7.7 Billion USD | 100.335% |
| Cellectis S.A. | 18 Thousand USD | 143422.222% |